Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 541 to 555 of 667 results for kidney or kidneys or renal

  1. Phosphate binders: In adults with stage 4 or 5 CKD, including those on dialysis, what is the clinical and cost effectiveness and safety of long-term calcium acetate combined with magnesium carbonate for controlling serum phosphate?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

  2. Multimorbidity: clinical assessment and management (NG56)

    This guideline covers optimising care for adults with multimorbidity (multiple long-term conditions) by reducing treatment burden (polypharmacy and multiple appointments) and unplanned care. It aims to improve quality of life by promoting shared decisions based on what is important to each person in terms of treatments, health priorities, lifestyle and goals. The guideline sets out which people are most likely to benefit from an approach to care that takes account of multimorbidity, how they can be identified and what the care involves.

  3. Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)

    This guidance has been updated and replaced by NICE technology appraisal guidance 432.

  4. Hyperphosphatemia in people with CKD stage 4 or 5: What are people with CKD and their family members and carers views and beliefs about taking oral phosphate binders?

    binders. Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

  5. Managing anaemia – optimal Hb levels for children and young people: What is the efficacy and safety of different aspirational haemoglobin (Hb) targets for children and young people with CKD undergoing treatment for anaemia?

    CKD. Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

  6. Further research on subcutaneous automated low-flow pump implantation for refractory ascites should report details of patient selection, the frequency of pump-related complications, and the need for regular albumin infusions.

    but well-recognised safety concerns, including device failure and acute kidney injury. Evidence on efficacy is limited in quantity....

  7. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

  8. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma (TA1090)

    Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.

  9. Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

    Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

  10. High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).

  11. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (HTG353)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.

  12. Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension (IPG418)

    Interventional procedures, IPG418 - Issued: January 2012 --> This guidance has been updated and replaced by NICE interventional procedures guidance 754.

  13. Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.